Please assess the completion status of the following clinical trial:

Trial Title: Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Patients must have undergone a matched related donor, matched unrelated donor or cord blood Hematopoietic Stem Cell Transplant (HSCT) over 6 months ago~* Patients currently on Desferal (desferrioxamine) therapy will require a one day wash out prior to the first dose of study drug~* Serum ferritin \>= 1500 ng/mL on two occasions two weeks apart at screening; samples must be obtained in the absence of concomitant infection~* Normal C-reactive protein level at screening~* Patients must be red cell transfusion independent for 2 months prior to enrollment~* Sexually active women must use an effective method of contraception, or must have undergone clinical documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal (defined as amenorrhea for at least 12 months)~* Written informed consent by the patient~Exclusion~* Chronic hepatic GVHD with serum total bilirubin over 2 mg/dL~* Known hypersensitivity to deferasirox~* Serum creatinine above the upper limit of normal~* AST or ALT \> 200 U/L during screening~* Clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive and ALT above the normal range)~* History of HIV positive test result (ELISA or Western blot)~* History of drug or alcohol abuse within the 12 months prior to enrollment~* ECOG Performance Status \> 2~* Patients with a diagnosis of or history of clinically relevant ocular toxicity related to iron chelation~* Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent study treatment~* Pregnancy (as documented in required screening laboratory test) or breast feeding~* Patients who received treatment with systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days or are planning to receive other investigational drugs while participating in the study~* Other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug~* History of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).